

# Vibeke Strand

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9564547/publications.pdf>

Version: 2024-02-01

282  
papers

18,850  
citations

18482

62  
h-index

13379

130  
g-index

294  
all docs

294  
docs citations

294  
times ranked

14427  
citing authors

#	ARTICLE	IF	CITATIONS
1	American college of rheumatology preliminary definition of improvement in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1995, 38, 727-735.	6.7	2,531
2	Rheumatoid arthritis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18001.	30.5	1,441
3	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. <i>Arthritis and Rheumatism</i> , 2011, 63, 573-586.	6.7	864
4	Developing Core Outcome Measurement Sets for Clinical Trials: OMERACT Filter 2.0. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 745-753.	5.0	625
5	Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate. <i>Archives of Internal Medicine</i> , 1999, 159, 2542.	3.8	614
6	Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. <i>Arthritis and Rheumatism</i> , 2008, 58, 3319-3329.	6.7	539
7	OMERACT: An international initiative to improve outcome measurement in rheumatology. <i>Trials</i> , 2007, 8, 38.	1.6	420
8	Novel evidence-based systemic lupus erythematosus responder index. <i>Arthritis and Rheumatism</i> , 2009, 61, 1143-1151.	6.7	397
9	Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety) Trial. <i>Arthritis and Rheumatism</i> , 2007, 49, 1473-1483.	6.7	431
10	Concomitant Leflunomide Therapy in Patients with Active Rheumatoid Arthritis despite Stable Doses of Methotrexate. <i>Annals of Internal Medicine</i> , 2002, 137, 726.	3.9	287
11	Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. <i>Arthritis and Rheumatism</i> , 2001, 44, 1984-1992.	6.7	275
12	High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 785-791.	0.9	269
13	Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebo-controlled, multicentre study. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 183-190.	0.9	266
14	Immunogenicity of Biologics in Chronic Inflammatory Diseases: A Systematic Review. <i>BioDrugs</i> , 2017, 31, 299-316.	4.6	241
15	LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: Results from a randomized, double-blind, placebo-controlled study. <i>Arthritis and Rheumatism</i> , 2003, 48, 442-454.	6.7	222
16	International patient and physician consensus on a psoriatic arthritis core outcome set for clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 673-680.	0.9	194
17	Relationship between anti-double-stranded DNA antibodies and exacerbation of renal disease in patients with systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2005, 52, 1129-1137.	6.7	187
18	Systematic review and meta-analysis of serious infections with tofacitinib and biologic disease-modifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 362.	3.5	181

#	ARTICLE	IF	CITATIONS
19	Biologic therapies in rheumatology: lessons learned, future directions. <i>Nature Reviews Drug Discovery</i> , 2007, 6, 75-92.	46.4	178
20	The role of biosimilars in the treatment of rheumatic diseases. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 322-328.	0.9	166
21	The changing landscape of biosimilars in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 974-982.	0.9	160
22	Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: Sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2000, 43, 506.	6.7	155
23	Assessment of physical function and participation in chronic pain clinical trials: IMMPACT/OMERACT recommendations. <i>Pain</i> , 2016, 157, 1836-1850.	4.2	152
24	Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: A double-blind, randomized, placebo-controlled trial. <i>Arthritis and Rheumatism</i> , 2002, 46, 1820-1829.	6.7	149
25	Are COX-2 inhibitors preferable to non-selective non-steroidal anti-inflammatory drugs in patients with risk of cardiovascular events taking low-dose aspirin?. <i>Lancet, The</i> , 2007, 370, 2138-2151.	13.7	145
26	Connective Tissue Disease-associated Interstitial Lung Diseases (CTD-ILD) – Report from OMERACT CTD-ILD Working Group. <i>Journal of Rheumatology</i> , 2015, 42, 2168-2171.	2.0	142
27	Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2004, 50, 2858-2868.	6.7	133
28	Function and health-related quality of life: Results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 1999, 42, 1870-1878.	6.7	132
29	Identifying core domains to assess flare in rheumatoid arthritis: an OMERACT international patient and provider combined Delphi consensus. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1855-1860.	0.9	131
30	Comparison of health-related quality of life in rheumatoid arthritis, psoriatic arthritis and psoriasis and effects of etanercept treatment. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1143-1150.	0.9	129
31	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial. <i>Arthritis and Rheumatology</i> , 2020, 72, 1607-1620.	5.6	126
32	Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 838-844.	0.9	123
33	Optimal Strategies for Reporting Pain in Clinical Trials and Systematic Reviews: Recommendations from an OMERACT 12 Workshop. <i>Journal of Rheumatology</i> , 2015, 42, 1962-1970.	2.0	116
34	Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebo-controlled, multicentre studies (ALLEVIATE) and follow-up. <i>Rheumatology</i> , 2013, 52, 1313-1322.	1.9	115
35	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. <i>Drug Safety</i> , 2016, 39, 755-762.	3.2	112
36	Newer Biological Agents in Rheumatoid Arthritis. <i>Drugs</i> , 2010, 70, 121-145.	10.9	111

#	ARTICLE	IF	CITATIONS
37	Efficacy and safety of an interleukin 6 monoclonal antibody for the treatment of systemic lupus erythematosus: a phase II dose-ranging randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 534-542.	0.9	111
38	The term "non-radiographic axial spondyloarthritis"™ is much more important to classify than to diagnose patients with axial spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 791-794.	0.9	105
39	OMERACT Filter 2.1: Elaboration of the Conceptual Framework for Outcome Measurement in Health Intervention Studies. <i>Journal of Rheumatology</i> , 2019, 46, 1021-1027.	2.0	97
40	Spondyloarthritis Is Associated with Poor Function and Physical Health-Related Quality of Life. <i>Journal of Rheumatology</i> , 2009, 36, 1012-1020.	2.0	96
41	Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1522-1528.	2.0	93
42	Worker productivity outcome measures in arthritis. <i>Journal of Rheumatology</i> , 2007, 34, 1372-80.	2.0	90
43	Improvements in health-related quality of life after treatment with tocilizumab in patients with rheumatoid arthritis refractory to tumour necrosis factor inhibitors: results from the 24-week randomized controlled RADIATE study. <i>Rheumatology</i> , 2012, 51, 1860-1869.	1.9	85
44	Patient Burden of Axial Spondyloarthritis. <i>Journal of Clinical Rheumatology</i> , 2017, 23, 383-391.	0.9	85
45	Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. <i>American Journal of Managed Care</i> , 2008, 14, 234-54.	1.1	82
46	Safety and efficacy of US-approved viscosupplements for knee osteoarthritis: a systematic review and meta-analysis of randomized, saline-controlled trials. <i>Journal of Pain Research</i> , 2015, 8, 217.	2.0	79
47	Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. <i>Rheumatology</i> , 2017, 56, 46-57.	1.9	79
48	Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1592-1600.	6.7	78
49	Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled trial. <i>Arthritis Research and Therapy</i> , 2009, 11, R170.	3.5	78
50	Prevalence of Axial Spondyloarthritis in United States Rheumatology Practices: Assessment of SpondyloArthritis International Society Criteria Versus Rheumatology Expert Clinical Diagnosis. <i>Arthritis Care and Research</i> , 2013, 65, 1299-1306.	3.4	78
51	Secukinumab improves patient-reported outcomes in subjects with active psoriatic arthritis: results from a randomised phase III trial (FUTURE 1). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 203-207.	0.9	78
52	Qualifying Unmet Needs and Improving Standards of Care in Psoriatic Arthritis. <i>Arthritis Care and Research</i> , 2014, 66, 1759-1766.	3.4	73
53	Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2005, 5, 317-326.	1.4	72
54	Effects of the Cyclooxygenase-2 Specific Inhibitor Valdecoxib Versus Nonsteroidal Antiinflammatory Agents and Placebo on Cardiovascular Thrombotic Events in Patients with Arthritis. <i>American Journal of Therapeutics</i> , 2004, 11, 244-250.	0.9	71

#	ARTICLE	IF	CITATIONS
55	The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 814-826.	2.9	70
56	Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 590-601.	2.0	68
57	The impact of rheumatoid arthritis and treatment on patients' lives. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S32-40.	0.8	68
58	Core Domain Set Selection According to OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1014-1020.	2.0	65
59	Combination leflunomide and methotrexate (MTX) therapy for patients with active rheumatoid arthritis failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo controlled trial. <i>Journal of Rheumatology</i> , 2004, 31, 1521-31.	2.0	65
60	Radiographic data from recent randomized controlled trials in rheumatoid arthritis: What have we learned?. <i>Arthritis and Rheumatism</i> , 2003, 48, 21-34.	6.7	64
61	Epratuzumab for patients with moderate to severe flaring SLE: health-related quality of life outcomes and corticosteroid use in the randomized controlled ALLEVIATE trials and extension study SL0006. <i>Rheumatology</i> , 2014, 53, 502-511.	1.9	64
62	Survival and quality of life in rheumatoid arthritis-associated interstitial lung disease after lung transplantation. <i>Journal of Heart and Lung Transplantation</i> , 2014, 33, 514-520.	0.6	64
63	Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study. <i>Arthritis and Rheumatology</i> , 2019, 71, 878-891.	5.6	64
64	Interpretation of chronic pain clinical trial outcomes: IMMPACT recommended considerations. <i>Pain</i> , 2020, 161, 2446-2461.	4.2	64
65	The risk of cardiovascular thrombotic events with selective cyclooxygenase-2 inhibitors. <i>Arthritis and Rheumatism</i> , 2002, 47, 349-355.	6.7	63
66	Improvements in patient-reported outcomes with apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of moderate to severe psoriasis: results from a phase IIb randomized, controlled study. <i>Health and Quality of Life Outcomes</i> , 2013, 11, 82.	2.4	63
67	Clinical, laboratory and health-related quality of life correlates of Systemic Lupus Erythematosus Responder Index response: a post hoc analysis of the phase 3 belimumab trials. <i>Lupus Science and Medicine</i> , 2014, 1, e000031.	2.7	63
68	Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1495-1501.	0.9	63
69	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. <i>Rheumatology</i> , 2016, 55, 1031-1041.	1.9	62
70	Tofacitinib in Combination With Conventional Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Randomized Controlled Trial. <i>Arthritis Care and Research</i> , 2017, 69, 592-598.	3.4	62
71	Instrument Selection Using the OMERACT Filter 2.1: The OMERACT Methodology. <i>Journal of Rheumatology</i> , 2019, 46, 1028-1035.	2.0	61
72	Certolizumab pegol plus methotrexate provides broad relief from the burden of rheumatoid arthritis: analysis of patient-reported outcomes from the RAPID 2 trial. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 996-1002.	0.9	60

#	ARTICLE	IF	CITATIONS
73	Improved Health-related Quality of Life and Physical Function in Patients with Refractory Chronic Gout Following Treatment with Pegloticase: Evidence from Phase III Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2012, 39, 1450-1457.	2.0	59
74	Health-related Quality of Life Outcomes of Adalimumab for Patients with Early Rheumatoid Arthritis: Results from a Randomized Multicenter Study. <i>Journal of Rheumatology</i> , 2012, 39, 63-72.	2.0	58
75	Patient Expectations and Perceptions of Goal-setting Strategies for Disease Management in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2015, 42, 2046-2054.	2.0	58
76	Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial. <i>Arthritis Research and Therapy</i> , 2016, 18, 198.	3.5	56
77	Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. <i>Rheumatology</i> , 2010, 49, 1900-1910.	1.9	55
78	Outcome measures in osteoarthritis: Randomized controlled trials. <i>Current Rheumatology Reports</i> , 2004, 6, 20-30.	4.7	54
79	Updating the OMERACT Filter: Implications for Patient-reported Outcomes. <i>Journal of Rheumatology</i> , 2014, 41, 1011-1015.	2.0	54
80	Predictors of self-reported health-related quality of life in systemic lupus erythematosus. <i>Rheumatology</i> , 2013, 52, 1651-1657.	1.9	53
81	Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. <i>Arthritis Research and Therapy</i> , 2015, 17, 307.	3.5	53
82	Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry. <i>Rheumatology and Therapy</i> , 2017, 4, 489-502.	2.3	51
83	Tofacitinib With Methotrexate in Third-Line Treatment of Patients With Active Rheumatoid Arthritis: Patient-Reported Outcomes From a Phase III Trial. <i>Arthritis Care and Research</i> , 2015, 67, 475-483.	3.4	50
84	Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. <i>RMD Open</i> , 2016, 2, e000308.	3.8	50
85	A systematic review of measurement properties of patient reported outcome measures in psoriatic arthritis: A GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 47, 654-665.	3.4	50
86	Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. <i>Journal of Rheumatology</i> , 2005, 32, 583-9.	2.0	50
87	Discordance between patient and physician assessments of global disease activity in rheumatoid arthritis and association with work productivity. <i>Arthritis Research and Therapy</i> , 2016, 18, 114.	3.5	49
88	Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond. <i>RMD Open</i> , 2019, 5, e000808.	3.8	46
89	Development and Validation of the Lupus Impact Tracker: A Patient-Completed Tool for Clinical Practice to Assess and Monitor the Impact of Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2014, 66, 1542-1550.	3.4	45
90	Leflunomide for the treatment of rheumatoid arthritis. <i>The Cochrane Library</i> , 2002, , CD002047.	2.8	44

#	ARTICLE	IF	CITATIONS
91	Health-related quality of life in systemic sclerosis compared with other rheumatic diseases: a cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 61.	3.5	44
92	Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broadenâ€”a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs. <i>RMD Open</i> , 2019, 5, e000806.	3.8	44
93	Health-related quality of life in patients with systemic lupus erythematosus: an update. <i>Annals of the Academy of Medicine, Singapore</i> , 2007, 36, 115-22.	0.4	44
94	PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials. <i>Journal of Rheumatology</i> , 2019, 46, 990-995.	2.0	43
95	Immunogenicity of biologic agents in rheumatology. <i>Nature Reviews Rheumatology</i> , 2021, 17, 81-97.	8.0	43
96	Patient-reported Health-related Quality of Life with Apremilast for Psoriatic Arthritis: A Phase II, Randomized, Controlled Study. <i>Journal of Rheumatology</i> , 2013, 40, 1158-1165.	2.0	42
97	Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 697-700.	2.0	42
98	Successful Stepwise Development of Patient Research Partnership: 14 Yearsâ€™ Experience of Actions and Consequences in Outcome Measures in Rheumatology (OMERACT). <i>Patient</i> , 2017, 10, 141-152.	2.7	41
99	The cost savings of biosimilars can help increase patient access and lift the financial burden of health care systems. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 52, 151939.	3.4	41
100	Measuring outcomes in systemic lupus erythematosus clinical trials. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2011, 11, 455-468.	1.4	40
101	Review: The Utility of Magnetic Resonance Imaging for Assessing Structural Damage in Randomized Controlled Trials in Rheumatoid Arthritis. <i>Arthritis and Rheumatism</i> , 2013, 65, 2513-2523.	6.7	40
102	Association of Blood Concentrations of Complement Split Product <sc>C3</sc> and Serum C3 With Systemic Lupus Erythematosus Disease Activity. <i>Arthritis and Rheumatology</i> , 2019, 71, 420-430.	5.6	39
103	Sustained efficacy of certolizumab pegol added to methotrexate in the treatment of rheumatoid arthritis: 2-year results from the RAPID 1 trial. <i>Rheumatology</i> , 2012, 51, 1628-1638.	1.9	38
104	Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report. <i>Journal of Rheumatology</i> , 2019, 46, 996-1005.	2.0	36
105	Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidence from randomized controlled trials. <i>American Journal of Managed Care</i> , 2007, 13 Suppl 9, S237-51.	1.1	36
106	Systematic literature review of domains assessed in psoriatic arthritis to inform the update of the psoriatic arthritis core domain set. <i>RMD Open</i> , 2016, 2, e000217.	3.8	35
107	Comparison of the Sensitivity to Change of the 36â€”item Short Form Health Survey and the Lupus Quality of Life Measure Using Various Definitions of Minimum Clinically Important Differences in Patients With Active Systemic Lupus Erythematosus. <i>Arthritis Care and Research</i> , 2018, 70, 125-133.	3.4	35
108	Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents. <i>BioDrugs</i> , 2020, 34, 27-37.	4.6	35

#	ARTICLE	IF	CITATIONS
109	Randomized controlled trial design in rheumatoid arthritis: the past decade. <i>Arthritis Research and Therapy</i> , 2009, 11, 205.	3.5	34
110	Enhanced Patient Involvement and the Need to Revise the Core Set – Report from the Psoriatic Arthritis Working Group at OMERACT 2014. <i>Journal of Rheumatology</i> , 2015, 42, 2198-2203.	2.0	34
111	Establishing an Updated Core Domain Set for Studies in Juvenile Idiopathic Arthritis: A Report from the OMERACT 2018 JIA Workshop. <i>Journal of Rheumatology</i> , 2019, 46, 1006-1013.	2.0	34
112	Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019. <i>Drug Safety</i> , 2021, 44, 889-897.	3.2	34
113	Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitors. <i>RMD Open</i> , 2017, 3, e000416.	3.8	33
114	Tumor Necrosis Factor Antagonist Responsiveness in a United States Rheumatoid Arthritis Cohort. <i>American Journal of Medicine</i> , 2008, 121, 532-538.	1.5	32
115	Long-Term Impact of Belimumab on Health-Related Quality of Life and Fatigue in Patients With Systemic Lupus Erythematosus: Six Years of Treatment. <i>Arthritis Care and Research</i> , 2019, 71, 829-838.	3.4	32
116	Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2018, 20, 129.	3.5	31
117	Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial. <i>Arthritis Research and Therapy</i> , 2019, 21, 64.	3.5	31
118	Evaluation of Minimally Invasive, Ultrasound-guided Synovial Biopsy Techniques by the OMERACT Filter – Determining Validation Requirements. <i>Journal of Rheumatology</i> , 2016, 43, 208-213.	2.0	30
119	Standardisation of synovial biopsy analyses in rheumatic diseases: a consensus of the EULAR Synovitis and OMERACT Synovial Tissue Biopsy Groups. <i>Arthritis Research and Therapy</i> , 2018, 20, 265.	3.5	29
120	Functional impairment measurement in psoriatic arthritis: Importance and challenges. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 436-448.	3.4	29
121	Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs. <i>Arthritis Research and Therapy</i> , 2019, 21, 263.	3.5	29
122	Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT. <i>Arthritis Research and Therapy</i> , 2019, 21, 272.	3.5	29
123	Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial. <i>RMD Open</i> , 2019, 5, e001040.	3.8	28
124	Evaluation and Management of the Patient With Suspected Inflammatory Spine Disease. <i>Mayo Clinic Proceedings</i> , 2017, 92, 555-564.	3.0	27
125	Engaging Stakeholders and Promoting Uptake of OMERACT Core Outcome Instrument Sets. <i>Journal of Rheumatology</i> , 2017, 44, 1551-1559.	2.0	27
126	Ixekizumab improves patient-reported outcomes up to 52 weeks in bDMARD-naïve patients with active psoriatic arthritis (SPIRIT-P1). <i>Rheumatology</i> , 2018, 57, 1777-1788.	1.9	27



#	ARTICLE	IF	CITATIONS
127	Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study. <i>RMD Open</i> , 2019, 5, e000889.	3.8	27
128	Treatment of Osteoarthritis with Continuous Versus Intermittent Celecoxib. <i>Journal of Rheumatology</i> , 2011, 38, 2625-2634.	2.0	26
129	A first step to assess harm and benefit in clinical trials in one scale. <i>Journal of Clinical Epidemiology</i> , 2010, 63, 627-632.	5.0	25
130	The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar. <i>Current Medical Research and Opinion</i> , 2017, 33, 993-1003.	1.9	25
131	Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review. <i>Lupus Science and Medicine</i> , 2020, 7, e000373.	2.7	25
132	Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting. <i>Journal of Rheumatology</i> , 2016, 43, 965-969.	2.0	24
133	Secukinumab provides rapid and sustained pain relief in psoriatic arthritis over 2 years: results from the FUTURE 2 study. <i>Arthritis Research and Therapy</i> , 2018, 20, 113.	3.5	24
134	Lessons learned from clinical trials in SLE. <i>Autoimmunity Reviews</i> , 2007, 6, 209-214.	5.8	23
135	Putting the value into biosimilar decision making. <i>Autoimmunity Reviews</i> , 2014, 13, 678-684.	5.8	23
136	Validation of pain and patient global scales in chronic gout: data from two randomised controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1277-1281.	0.9	22
137	AJC Editor's Consensus: Selective and Nonselective Nonsteroidal Anti-Inflammatory Drugs and Cardiovascular Risk. <i>American Journal of Cardiology</i> , 2010, 106, 873-884.	1.6	21
138	Damage and Progression on Radiographs in Individual Joints: Data from Pivotal Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2011, 38, 2018-2022.	2.0	20
139	Generic Versus Disease-specific Measures of Health-related Quality of Life in Systemic Lupus Erythematosus. <i>Journal of Rheumatology</i> , 2011, 38, 1821-1823.	2.0	20
140	Is Chronic Pain a Disease in Its Own Right? Discussions from a Pre-OMERACT 2014 Workshop on Chronic Pain. <i>Journal of Rheumatology</i> , 2015, 42, 1947-1953.	2.0	20
141	Classification and Outcome Measures for Psoriatic Arthritis. <i>Frontiers in Medicine</i> , 2018, 5, 246.	2.6	20
142	Economic Burden of Patients with Inadequate Response to Targeted Immunomodulators for Rheumatoid Arthritis. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 344-352.	0.9	20
143	Relationship of pain and fatigue with health-related quality of life and work in patients with psoriatic arthritis on TNFi: results of a multi-national real-world study. <i>RMD Open</i> , 2020, 6, e001240.	3.8	20
144	Impact of belimumab on patient-reported outcomes in systemic lupus erythematosus: review of clinical studies. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 1-7.	1.2	19

#	ARTICLE	IF	CITATIONS
145	Measurement properties of the minimal disease activity criteria for psoriatic arthritis. <i>RMD Open</i> , 2019, 5, e001002.	3.8	19
146	Development and Validation of a Novel Evidence-Based Lupus Multivariable Outcome Score for Clinical Trials. <i>Arthritis and Rheumatology</i> , 2018, 70, 1450-1458.	5.6	18
147	Secukinumab treatment in rheumatoid arthritis is associated with incremental benefit in the clinical outcomes and HRQoL improvements that exceed minimally important thresholds. <i>Health and Quality of Life Outcomes</i> , 2014, 12, 31.	2.4	17
148	Short-term changes on MRI predict long-term changes on radiography in rheumatoid arthritis: an analysis by an OMERACT Task Force of pooled data from four randomised controlled trials. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 992-997.	0.9	17
149	Discordant patient-physician assessments of disease activity and its persistence adversely impact quality of life and work productivity in US Hispanics with rheumatoid arthritis. <i>RMD Open</i> , 2017, 3, e000551.	3.8	17
150	A Single Intra-Articular Injection of Gel-200 for Treatment of Symptomatic Osteoarthritis of the Knee Is More Effective than Phosphate Buffered Saline at 6 Months: A Subgroup Analysis of a Multicenter, Randomized Controlled Trial. <i>Cartilage</i> , 2019, 10, 417-422.	2.7	17
151	High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab. <i>Arthritis Research and Therapy</i> , 2020, 22, 250.	3.5	17
152	Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib. <i>Arthritis Research and Therapy</i> , 2020, 22, 243.	3.5	17
153	Upadacitinib improves patient-reported outcomes <i>vs</i> placebo or adalimumab in patients with rheumatoid arthritis: results from SELECT-COMPARE. <i>Rheumatology</i> , 2021, 60, 5583-5594.	1.9	17
154	Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated Diseases. <i>Clinical Therapeutics</i> , 2021, 43, 1392-1407.e1.	2.5	17
155	Physician Global Assessment International Standardisation Consensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	3.9	17
156	Evidence for safety of retreatment with a single intra-articular injection of Gel-200 for treatment of osteoarthritis of the knee from the double-blind pivotal and open-label retreatment clinical trials. <i>BMC Musculoskeletal Disorders</i> , 2016, 17, 240.	1.9	16
157	Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000232.	3.8	16
158	Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials. <i>RMD Open</i> , 2017, 3, e000496.	3.8	16
159	GRAPPA-OMERACT initiative to standardise outcomes in psoriatic arthritis clinical trials and longitudinal observational studies. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, e23-e23.	0.9	16
160	Adjustment of the multi-biomarker disease activity score to account for age, sex and adiposity in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2019, 58, 874-883.	1.9	16
161	Clinical response to nonsteroidal antiinflammatory drugs. <i>Arthritis and Rheumatism</i> , 1997, 40, 1940-1943.	6.7	15
162	Magnetic Resonance Imaging in Rheumatoid Arthritis Clinical Trials: Emerging Patterns Based on Recent Experience. <i>Journal of Rheumatology</i> , 2011, 38, 2023-2030.	2.0	15

#	ARTICLE	IF	CITATIONS
163	Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators. <i>Journal of Medical Economics</i> , 2017, 20, 703-714.	2.1	15
164	Adiposity in Juvenile Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2018, 45, 411-418.	2.0	15
165	Upadacitinib monotherapy improves patient-reported outcomes in rheumatoid arthritis: results from SELECT-EARLY and SELECT-MONOTHERAPY. <i>Rheumatology</i> , 2021, 60, 3209-3221.	1.9	14
166	The GRAPPA-OMERACT Psoriatic Arthritis Working Group at the 2018 Annual Meeting: Report and Plan for Completing the Core Outcome Measurement Set. <i>Journal of Rheumatology</i> , 2019, 95, 33-37.	2.0	14
167	Improvement in Patient-Reported Outcomes in Patients with Psoriatic Arthritis Treated with Upadacitinib Versus Placebo or Adalimumab: Results from SELECT-PsA 1. <i>Rheumatology and Therapy</i> , 2021, 8, 1789-1808.	2.3	14
168	Effect of tofacitinib on pain, fatigue, health-related quality of life and work productivity in patients with active ankylosing spondylitis: results from a phase III, randomised, double-blind, placebo-controlled trial. <i>RMD Open</i> , 2022, 8, e002253.	3.8	14
169	Outcomes and costs of incorporating a multibiomarker disease activity test in the management of patients with rheumatoid arthritis. <i>Rheumatology</i> , 2015, 54, 1640-1649.	1.9	13
170	Impact of tocilizumab administered intravenously or subcutaneously on patient-reported quality-of-life outcomes in patients with rheumatoid arthritis. <i>RMD Open</i> , 2018, 4, e000602.	3.8	13
171	Performance of composite measures used in a trial of etanercept and methotrexate as monotherapy or in combination in psoriatic arthritis. <i>Rheumatology</i> , 2021, 60, 1137-1147.	1.9	13
172	Endorsement of the OMERACT core domain set for shared decision making interventions in rheumatology trials: Results from a multi-stepped consensus-building approach. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 593-600.	3.4	13
173	Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report. <i>Journal of Rheumatology</i> , 2017, 44, 1894-1898.	2.0	12
174	The Role of Patient-Reported Outcomes in Systemic Lupus Erythematosus. <i>Current Treatment Options in Rheumatology</i> , 2017, 3, 308-321.	1.4	12
175	Pain and Fatigue in Patients With Ankylosing Spondylitis Treated With Tumor Necrosis Factor Inhibitors. <i>Journal of Clinical Rheumatology</i> , 2021, 27, e446-e455.	0.9	12
176	Secukinumab provides rapid and persistent relief in pain and fatigue symptoms in patients with ankylosing spondylitis irrespective of baseline C-reactive protein levels or prior tumour necrosis factor inhibitor therapy: 2-year data from the MEASURE 2 study. <i>Clinical and Experimental Rheumatology</i> , 2019, 37, 260-269.	0.8	12
177	Evidence for Updating the Core Domain Set of Outcome Measures for Juvenile Idiopathic Arthritis: Report from a Special Interest Group at OMERACT 2016. <i>Journal of Rheumatology</i> , 2017, 44, 1884-1888.	2.0	11
178	Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group. <i>Journal of Rheumatology</i> , 2017, 44, 1916-1919.	2.0	11
179	The impact of sex and disease classification on patient-reported outcome measures in axial spondyloarthritis: a descriptive prospective cross-sectional study. <i>Arthritis Research and Therapy</i> , 2019, 21, 221.	3.5	11
180	Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative. <i>Journal of Rheumatology</i> , 2019, 46, 1159-1163.	2.0	11

#	ARTICLE	IF	CITATIONS
181	Efficacy and safety of tregalizumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase IIb, randomised, placebo-controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 495-499.	0.9	10
182	Improvement of Functioning and Health With Ixekizumab in the Treatment of Active Nonradiographic Axial Spondyloarthritis in a <sc>52â€œWeek</sc>, Randomized, Controlled Trial. <i>Arthritis Care and Research</i> , 2022, 74, 451-460.	3.4	10
183	Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: <sc>Longâ€œTerm</sc> Results of Two Phase <sc>III</sc> Randomized Controlled Trials. <i>Arthritis Care and Research</i> , 2022, 74, 759-767.	3.4	10
184	Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting. <i>Journal of Rheumatology</i> , 2018, 94, 17-25.	2.0	10
185	Counterpoint from the trenches: A pragmatic approach to therapeutic trials in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2004, 50, 1344-1347.	6.7	9
186	Low-dose SoluMatrix diclofenac in the treatment of osteoarthritis: A 1-year, open-label, Phase III safety study. <i>Postgraduate Medicine</i> , 2015, 127, 517-528.	2.0	9
187	Reanalysis of the Multiâ€œBiomarker Disease Activity Score for Assessing Disease Activity in the Abatacept Versus Adalimumab Comparison in Biologicâ€œNaive Rheumatoid Arthritis Subjects with Background Methotrexate Study: Comment on the Article by Fleischmann et al. <i>Arthritis and Rheumatology</i> , 2017, 69, 863-865.	5.6	9
188	Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials. <i>Clinical Rheumatology</i> , 2018, 37, 2043-2053.	2.2	9
189	Improved patient-reported outcomes in patients with psoriatic arthritis treated with abatacept: results from a phase 3 trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 269.	3.5	9
190	Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses. <i>Rheumatology and Therapy</i> , 2018, 5, 341-353.	2.3	9
191	Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale. <i>Journal of Rheumatology</i> , 2019, 46, 1259-1267.	2.0	9
192	Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension. <i>RMD Open</i> , 2019, 5, e001017.	3.8	9
193	Assessing the effect of interventions for axial spondyloarthritis according to the endorsed ASAS/OMERACT core outcome set: a meta-research study of trials included in Cochrane reviews. <i>Arthritis Research and Therapy</i> , 2020, 22, 177.	3.5	9
194	Harmonizing Pain Outcome Measures: Results of the Pre-OMERACT Meeting on Partnerships for Consensus on Patient-important Pain Outcome Domains Between the Cochrane Musculoskeletal Group and OMERACT. <i>Journal of Rheumatology</i> , 2015, 42, 1943-1946.	2.0	8
195	Local Effects Following Single and Repeat Intra-Articular Injections of Triamcinolone Acetonide Extended-Release: Results from Three Nonclinical Toxicity Studies in Dogs. <i>Rheumatology and Therapy</i> , 2018, 5, 475-498.	2.3	8
196	Improving Benefit-harm Assessment of Therapies from the Patient Perspective: OMERACT Premeeting Toward Consensus on Core Sets for Randomized Controlled Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1053-1058.	2.0	8
197	Dual trajectories of fatigue and disease activity in an inception cohort of adults with systemic lupus erythematosus over 10 years. <i>Lupus</i> , 2021, 30, 578-586.	1.6	8
198	Report of the Skin Research Working Groups From the GRAPPA 2020 Annual Meeting. <i>Journal of Rheumatology</i> , 2021, , jrheum.201668.	2.0	8

#	ARTICLE	IF	CITATIONS
199	Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison. <i>European Journal of Rheumatology</i> , 2018, 5, 216-223.	0.6	8
200	Patient-Reported Outcomes in Psoriatic Arthritis Patients with an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drugs: SELECT-PsA 2. <i>Rheumatology and Therapy</i> , 2021, 8, 1827-1844.	2.3	8
201	Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease. <i>Advances in Therapy</i> , 2022, 39, 738-753.	2.9	8
202	Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda. <i>Journal of Rheumatology</i> , 2015, 42, 1934-1942.	2.0	7
203	Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2019, 46, 1164-1167.	2.0	7
204	Ixekizumab Improves Functioning and Health in the Treatment of Radiographic Axial Spondyloarthritis: Week 52 Results from 2 Pivotal Studies. <i>Journal of Rheumatology</i> , 2021, 48, 188-197.	2.0	7
205	Ixekizumab Improves Patient-Reported Outcomes in Non-Radiographic Axial Spondyloarthritis: Results from the Coast-X Trial. <i>Rheumatology and Therapy</i> , 2021, 8, 135-150.	2.3	7
206	OMERACT consensus-based operational definition of contextual factors in rheumatology clinical trials: A mixed methods study. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 601-606.	3.4	7
207	Clinical meaningfulness of a British Isles Lupus Assessment Group-based Composite Lupus Assessment response in terms of patient-reported outcomes in moderate to severe systemic lupus erythematosus: a post-hoc analysis of the phase 3 TULIP-1 and TULIP-2 trials of anifrolumab. <i>Lancet Rheumatology</i> , The, 2022, 4, e198-e207.	3.9	7
208	Latent profile analysis approach to the relationship between patient and physician global assessments of rheumatoid arthritis activity. <i>RMD Open</i> , 2018, 4, e000695.	3.8	6
209	Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials. <i>Journal of Rheumatology</i> , 2019, 46, 1173-1178.	2.0	6
210	Economic burden of fatigue or morning stiffness among patients with rheumatoid arthritis: a retrospective analysis from real-world data. <i>Current Medical Research and Opinion</i> , 2020, 36, 161-168.	1.9	6
211	Clinical trial discrimination of physical function instruments for psoriatic arthritis: A systematic review. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 1158-1181.	3.4	6
212	Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks. <i>Rheumatology and Therapy</i> , 2020, 7, 759-774.	2.3	6
213	Outcomes Reported in Prospective Long-Term Observational Studies and Registries of Patients With Rheumatoid Arthritis Worldwide: An Outcome Measures in Rheumatology Systematic Review. <i>Arthritis Care and Research</i> , 2021, 73, 649-657.	3.4	6
214	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naïve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. <i>Modern Rheumatology</i> , 2021, 31, 534-542.	1.8	6
215	Interferon-directed therapies for the treatment of systemic lupus erythematosus: a critical update. <i>Clinical Rheumatology</i> , 2021, 40, 3027-3037.	2.2	6
216	Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: patient-reported outcomes from the 24-month Phase 3 ORAL Scan study. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 848-857.	0.8	6

#	ARTICLE	IF	CITATIONS
217	Clinical utility of therapy selection informed by predicted nonresponse to tumor necrosis factor- $\epsilon$ inhibitors: an analysis from the Study to Accelerate Information of Molecular Signatures (AIMS) in rheumatoid arthritis. <i>Expert Review of Molecular Diagnostics</i> , 2022, 22, 101-109.	3.1	6
218	Impact of Treatment With Biologic Agents on the Use of Mechanical Devices Among Rheumatoid Arthritis Patients in a Large US Patient Registry. <i>Arthritis Care and Research</i> , 2016, 68, 914-921.	3.4	5
219	Infections in the Era of Targeted Therapies: Mapping the Road Ahead. <i>Frontiers in Medicine</i> , 2020, 7, 336.	2.6	5
220	Appraisal of Candidate Instruments for Assessment of the Physical Function Domain in Patients with Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 58-66.	2.0	5
221	A pilot study to evaluate the safety and efficacy of treprostinil in the treatment of calcinosis in systemic sclerosis. <i>Rheumatology</i> , 2022, 61, 2441-2449.	1.9	5
222	OMERACT 10 Sharp Symposium: Important Findings in Examination of Imaging Methods for Measurement of Joint Damage in Rheumatoid Arthritis. <i>Journal of Rheumatology</i> , 2011, 38, 2009-2013.	2.0	4
223	Effect of Blood Loss on Physical Function in Arthritis Patients: A Pooled Analysis. <i>Health Outcomes Research in Medicine</i> , 2011, 2, e27-e38.	0.6	4
224	Importance of "meeting of the minds"™: patient-reported outcomes and MRI. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 473-475.	0.9	4
225	Trial Characteristics as Contextual Factors When Evaluating Targeted Therapies in Patients With Psoriatic Disease: A Meta-Epidemiologic Study. <i>Arthritis Care and Research</i> , 2018, 70, 1206-1217.	3.4	4
226	RMD commentary, JAK kinase inhibitors: a preferred alternative to TNF inhibitors?. <i>RMD Open</i> , 2021, 7, e001565.	3.8	4
227	Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT recommendations. <i>Pain</i> , 2022, 163, 1006-1018.	4.2	4
228	International Dermatology Outcome Measures (IDEOM): Report from the 2020 Annual Meeting. <i>Dermatology</i> , 2022, 238, 430-437.	2.1	4
229	OMERACT Filter 2.1 instrument selection for physical function domain in psoriatic arthritis: Provisional endorsement for HAQ-DI and SF-36 PF. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1117-1124.	3.4	4
230	Development of a patient-centered core domain set for prospective observational longitudinal outcome studies in rheumatoid arthritis: an OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 1113-1116.	3.4	4
231	Change in psoriatic arthritis outcome measures impacts SF-36 physical and mental component scores differently: an observational cohort study. <i>Rheumatology Advances in Practice</i> , 2021, 5, rkab076.	0.7	4
232	Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response. <i>Current Rheumatology Reports</i> , 2022, 24, 12-19.	4.7	4
233	Recent Developments for Optimal End-Points in Rheumatoid Arthritis Clinical Studies. <i>Disease Management and Health Outcomes</i> , 2000, 8, 87-97.	0.4	3
234	New therapies in development for autoimmune diseases: their rationale for combination treatment. <i>Seminars in Immunopathology</i> , 2001, 23, 43-61.	4.0	3

#	ARTICLE	IF	CITATIONS
235	Response to M. Boersâ€™ concerns about spydergrams. <i>Journal of Clinical Epidemiology</i> , 2013, 66, 247-252.	5.0	3
236	Improvements in Fatigue in 1536 Patients with Rheumatoid Arthritis and Correlation with Other Treatment Outcomes: A Post Hoc Analysis of Three Randomized Controlled Trials of Abatacept. <i>Rheumatology and Therapy</i> , 2017, 4, 99-109.	2.3	3
237	A Pooled Analysis of Two Multicenter, Randomized Controlled Trials of a Single Intra-articular Injection of Gel-200 for Treatment of Osteoarthritis of the Knee. <i>Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders</i> , 2018, 11, 117954411877306.	1.2	3
238	Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis. <i>Rheumatology International</i> , 2020, 40, 1021-1028.	3.0	3
239	Test-retest Reliability for HAQ-DI and SF-36 PF for the Measurement of Physical Function in Psoriatic Arthritis. <i>Journal of Rheumatology</i> , 2021, 48, 1547-1551.	2.0	3
240	Harms reported by patients in rheumatology drug trials: a systematic review of randomized trials in the cochrane library from an OMERACT working group. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 607-617.	3.4	3
241	Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process. <i>Seminars in Arthritis and Rheumatism</i> , 2021, , .	3.4	3
242	The effect of secukinumab on patient-reported outcomes in patients with active psoriatic arthritis in a randomised phase 3 trial. <i>Lancet Rheumatology, The</i> , 2022, 4, e208-e219.	3.9	3
243	Patient-reported outcomes and realistic clinical endpoints for JAK inhibitors in rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2022, 18, 193-205.	3.0	3
244	Inhibition of structural joint damage progression with upadacitinib in rheumatoid arthritis: 1-year outcomes from the SELECT phase 3 program. <i>Rheumatology</i> , 2022, 61, 3246-3256.	1.9	3
245	Improvement in clinical disease activity index when treatment selection is informed by the tumor necrosis factor-Î³ inhibitor molecular signature response classifier: analysis from the study to accelerate information of molecular signatures in rheumatoid arthritis. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 801-807.	3.1	3
246	Patient-Reported Pain is Central to OMERACT Rheumatology Core Measurement Sets. <i>Drug Information Journal</i> , 2006, 40, 111-116.	0.5	2
247	A novel means to demonstrate early efficacy of a product in systemic lupus erythematosus. <i>Current Rheumatology Reports</i> , 2007, 9, 427-430.	4.7	2
248	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. <i>Quality of Life Research</i> , 2020, 29, 369-380.	3.1	2
249	New Treatments in Rheumatology: Biosimilars. <i>Current Treatment Options in Rheumatology</i> , 2020, 6, 325-336.	1.4	2
250	Relation Between Fatigue and ACR Response in Patients With Psoriatic Arthritis Treated With Tumor Necrosis Factor Inhibitor Therapy: A Population-based Cohort Study. <i>Journal of Rheumatology</i> , 2021, 48, 829-835.	2.0	2
251	Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2021, , jrheum.201679.	2.0	2
252	Measurement properties of radiographic outcome measures in Psoriatic Arthritis: A systematic review from the GRAPPA-OMERACT initiative. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 367-386.	3.4	2

#	ARTICLE	IF	CITATIONS
253	Ixekizumab improves spinal pain, function, fatigue, stiffness, and sleep in radiographic axial Spondyloarthritis: COAST-V/W 52-week results. <i>BMC Rheumatology</i> , 2021, 5, 35.	1.6	2
254	176â€¦Secukinumab provides sustained reduction in fatigue in patients with ankylosing spondylitis through three years: long-term results of two randomised double-blind placebo-controlled phase III studies. <i>Rheumatology</i> , 2018, 57, .	1.9	1
255	Patient-reported outcomes data in patients with psoriatic arthritis from a randomised trial of etanercept and methotrexate as monotherapy or in combination. <i>RMD Open</i> , 2021, 7, e001484.	3.8	1
256	What are the domains and outcome measures used in the existing neuropsychiatric systemic lupus erythematosus literature?. <i>Rheumatology</i> , 2021, 61, 6-7.	1.9	1
257	Biosimilars. , 2020, , 411-424.		1
258	Knowledge Translation for Patients: Methods to Support Patients' Participation in Decision making about Preference-Sensitive Treatment Options in Rheumatology. , 0, , 41-62.		1
259	Interleukin-6 inhibition–tolerability profile and clinical implications. <i>Bulletin of the NYU Hospital for Joint Diseases</i> , 2007, 65 Suppl 1, S21-4.	0.7	1
260	Plain Radiographic Instruments for Structural Damage in Peripheral Joints in Psoriatic Arthritis: A Report From the GRAPPA-OMERACT Working Group. <i>Journal of Rheumatology</i> , 2022, , jrheum.211322.	2.0	1
261	The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases. <i>Advances in Therapy</i> , 2022, 39, 767-778.	2.9	1
262	OMERACT: An Ongoing Evidence-Based Initiative to Improve the Quality of Outcome Measures in Rheumatology. , 0, , 19-24.		1
263	Patient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group. <i>Seminars in Arthritis and Rheumatism</i> , 2023, 58, 152028.	3.4	1
264	059â€¦The Impact of Intensive Treatment, Inflammation and Remission on Health-Related Quality of Life in Early and Established Rheumatoid Arthritis. <i>Rheumatology</i> , 0, , .	1.9	0
265	Ms. A.M. Taylor, et al reply. <i>Journal of Rheumatology</i> , 2016, 43, 826.2-827.	2.0	0
266	170â€¦Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved low disease activity related to psoriatic arthritis disease activity score. <i>Rheumatology</i> , 2018, 57, .	1.9	0
267	182â€¦Secukinumab provides sustained improvement in function, quality of life and fatigue over two years in patients who achieved disease activity index for psoriatic arthritis remission. <i>Rheumatology</i> , 2018, 57, .	1.9	0
268	175â€¦Comparative effectiveness of secukinumab and infliximab in psoriatic arthritis assessed by matching-adjusted indirect comparison using pivotal Phase III clinical trial data. <i>Rheumatology</i> , 2018, 57, .	1.9	0
269	Reply. <i>Arthritis and Rheumatology</i> , 2019, 71, 1590-1592.	5.6	0
270	54â€¦...Blood concentrations of complement split product iC3b and serum C3 associate with systemic lupus erythematosus disease activity. , 2019, , .		0



#	ARTICLE	IF	CITATIONS
271	THU0414â€¦COMPARISON OF INTRA-ARTICULAR SHAM AND VEHICLE INJECTIONS FROM A PHASE 2B TRIAL OF SM04690, A SMALL-MOLECULE WNT PATHWAY INHIBITOR FOR KNEE OSTEOARTHRITIS. , 2019, , .		0
272	P225â€¦Inhibition of structural joint damage with upadacitinib as monotherapy or in combination with MTX in patients with RA: one-year outcomes from the select Phase 3 programme. Rheumatology, 2020, 59, .	1.9	0
273	P213â€¦High baseline serum IL-6 predicts increased sarilumab treatment response for patient reported symptoms and health-related quality of life among RA patients with inadequate response to MTX. Rheumatology, 2020, 59, .	1.9	0
274	Minimizing efficacy differences between phase II and III RCTs. Nature Reviews Rheumatology, 2020, 16, 359-360.	8.0	0
275	Patient-Reported Outcomes in SLE. , 2021, , 213-227.		0
276	The Prognostic Value of Pain Phenotyping in Relation to Treatment Outcomes in Patients with Axial Spondyloarthritis Treated in Clinical Practice: A Prospective Cohort Study. Journal of Clinical Medicine, 2021, 10, 1469.	2.4	0
277	Long-term safety and efficacy of tofacitinib up to 48 months in psoriatic arthritis. Lancet Rheumatology, The, 2021, 3, e239-e240.	3.9	0
278	OMERACT 2020: A virtual (R)evolution. Seminars in Arthritis and Rheumatism, 2021, 51, 588-592.	3.4	0
279	Immune-mediated diseases and thromboembolic events: a modified Delphi panel. Current Medical Research and Opinion, 2021, 37, 1283-1291.	1.9	0
280	Fatigue and Pain Measurements in Systemic Lupus Erythematosus. , 2021, , 303-335.		0
281	Assessing disease activity and outcome in systemic lupus erythematosus. , 2015, , 1093-1098.		0
282	Selective T-cell costimulation modulation: a new approach to treating rheumatoid arthritis. American Journal of Orthopedics, 2007, 36, 8, 13-4.	0.7	0